Fig. 2.

Fig. 2.

Short-term assessment of vemurafenib pellets on BRAF^V600E zebrafish melanoma. (A) Schematic overview of drug-pellet free feeding administration, tumour response tracking and evaluation for each fish treated with vemurafenib or DMSO pellets. (B) Representative images of BRAF^V600E zebrafish melanoma progression under treatment with DMSO pellets. Zoomed regions are indicated by red dashed line boxes. Dotted lines outline the melanoma. Scale bars: 1 mm. (C) Quantification of melanoma size change each week (by fold) under treatment with DMSO pellets, comparing to the lesion imaged on the day pre-treatment. Fish receiving DMSO pellets, N=4; lesion count, n=6. Lesions from the same fish are presented in the same colour. The large lesion presented in B is indicated by round dots. (D) Representative images of BRAF^V600E zebrafish melanoma regressing under daily treatment with 100 mg/kg vemurafenib pellets. Dotted lines outline the melanoma. Scale bars: 1 mm. (E) Quantification of melanoma size change each week under daily treatment with 100 mg/kg vemurafenib pellets (by fold), compared to pre-treatment. Fish receiving 100 mg/kg vemurafenib pellets, N=3; lesion count, n=6. Lesions from the same fish are presented in the same colour. The lesion presented in D is indicated by round dots. (F) Representative images of BRAF^V600E zebrafish melanoma regressing under treatment with 200 mg/kg vemurafenib pellets. Scale bars: 1 mm. (G) Quantification of melanoma size change each week under daily treatment with 200 mg/kg pellets (by fold) for Cohort I, comparing to the lesion imaged on the day pre-treatment. Fish receiving 200 mg/kg vemurafenib pellets, N=4; lesion count, n=9. Lesions from the same fish are presented in the same colour. The lesion presented in F is indicated by round dots. (H) Quantification of melanoma size change each week under daily treatment with 200 mg/kg vemurafenib pellets (by fold) for Cohort II, comparing to the lesion imaged on the day pre-treatment. Fish receiving 200 mg/kg vemurafenib pellets, N=10; lesion count, n=22. Lesions from the same fish are presented in the same colour. (I) Waterfall plot ranking melanoma size change after 3-week daily treatment with DMSO, 100 mg/kg vemurafenib or 200 mg/kg vemurafenib pellets (by percentage), compared to each lesion imaged on the day pre-treatment. Fish receiving DMSO pellets, N=3; lesion count, n=5. Fish receiving 100 mg/kg vemurafenib pellets, N=3; lesion count, n=6. Fish receiving 200 mg/kg vemurafenib pellets (Cohort I), N=4; lesion count, n=9. Fish receiving 200 mg/kg vemurafenib pellets (Cohort II), N=10; lesion count, n=22. Lesions from the same fish are indicated with the same x-axis label. D, DMSO; V1, vemurafenib 100 mg/kg; V2C1, vemurafenib 200 mg/kg Cohort I; V2C2, vemurafenib 200 mg/kg Cohort II.